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The oral lichenoid disease (OLD) includes different chronic inflammatory processes such as oral lichen planus 
(OLP) and oral lichenoid lesions (OLL), both entities with controversial diagnosis and malignant potential.  Epi-
dermal growth factor receptor (EFGR) is an important oral carcinogenesis biomarker and overexpressed in several 
oral potentially malignant disorders. 
Objectives: To analyze the EGFR expression in the OLD to find differences between OLP and OLL, and to cor-
relate it with the main clinical and pathological features.
Material and Methods: Forty-four OLD cases were studied and classified according to their clinical (Group C1: 
only papular lesions / Group C2: papular and other lesions) and histopathological features (Group HT: OLP-typical 
/ Group HC: OLP-compatible) based in previous published criteria. Standard immunohistochemical identification 
of EGFR protein was performed. Comparative and descriptive statistical analyses were performed.
Results: Thirty-five cases (79.5%) showed EGFR overexpression without significant differences between clinical 
and histopathological groups (p<0.05). Histological groups showed significant differences in the EGFR expres-
sion pattern (p=0.016).
Conlusions: All OLD samples showed high EGFR expression. The type of clinical lesion was not related with 
EGFR expression; however, there are differences in the EGFR expression pattern between histological groups that 
may be related with a different biological profile and malignant risk.
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Introduction
Oral lichenoid disease (OLD) includes different chronic 
inflammatory processes with an immunological basis 
such as oral lichen planus (OLP) and oral lichenoid le-
sions (OLL) (1), both entities with controversial diag-
nosis and malignant potential (1-4). The clinical and 
histopathological links between OLD subtypes are the 
presence of lineal papular lesions with reticular pattern, 
usually associated with atrophic, erosive, ulcerative and 
plaque lesions; and the presence of predominantly lym-
phocytic chronic inflammatory infiltrate with a “band 
like” pattern and epithelial basal cell degeneration (1,5). 
Clinical and histopathological differentiation between 
OLP and OLL is difficult, frequently even impossible 
to establish (2,6). Nevertheless, it seems that this dif-
ferentiation is important, since some studies have dem-
onstrated that OLP and OLL have different malignant 
potential (1,7,8).
OLP malignant transformation rate has been reported to 
range between 0 to 5%, although it is considered not to 
exceed 1% (9-11). Due to the lack of strict and uniform 
diagnostic criteria for OLP, several studies have includ-
ed indistinctively cases of OLP and OLL and even other 
lesions with a recognized malignant potential but neither 
lichenoid features nor inflammatory etiology such as 
leukoplakia and erithroplakia (2,3,12). Interesting stud-
ies (7,8), have demonstrated that only lesions diagnosed 
as OLL (based on strict clinical and histopathological 
diagnostic criteria) showed malignant transformation 
risk, suggesting that the distinction of these processes 
is crucial for prognosis and treatment (2). Therefore, 
finding molecular differences between both processes 
is important. To the best of our knowledge, no studies 
have analyzed the immunohistochemical expression of 
biomarkers associated with oral carcinogenesis such as 
the epidermal growth factor receptor (EGFR) in OLP 
and OLL, using the van der Meij and van der Waal his-
tological diagnostic criteria (2).
EGFR is a transmembrane glycoprotein member of the 
Erb growth factor receptor family (Erb1 o EGFR, Erb2, 
Erb3 y Erb4) which has been associated with oral car-
cinogenesis (13-17). EGFR regulates several mechanisms 
involved in cell development and epithelial integrity (15). 
The EGFR has a tyrosine-kinase dependent action struc-
tured by extracellular, transmembrane and intracellular 
zones. The binding of the extracellular component to 
its respective ligands (EGF [epidermal growth factor], 
TGF-α [transforming growth factor], betaceluline, am-
phireguline and hereguline), activates multiple intracel-
lular stimulation and/or modulation pathways (Ras/Raf/
MAPK; P13K/AKT; PCLgamma; STATs) such as: cell 
proliferation, differentiation, inhibition of apoptosis, an-
giogenesis, migration and cellular invasion (16).
Some studies have demonstrated that EGFR is overex-
pressed in oral squamous cell carcinoma (OSCC) (16), 
and associated with positive lymph nodes in patients 
with head and neck carcinomas (HNC) (18,19). Further-
more, other studies (13-17) have demonstrated a pro-
gressive increase of EGFR expression, which was pro-
portional to the severity of premalignant lesions (13). 
Despite the strong association of EGFR overexpression 
with oral carcinogenesis of oral potentially malignant 
lesions (OPML), few studies have analyzed its expres-
sion in OLP (20,21), showing controversial results, and 
none in OLL. On one hand, Ebrahimi et al. (20) have 
observed low EGFR expression in OLP samples, in con-
trast, Kumagai et al. (21) observed a high expression in 
all their samples of OLP. 
Encouraged by the interesting and reproducible results 
obtained by van der Meij and van der Waal (7,8) and 
the strong association of EGFR expression and oral car-
cinogenesis, the aim of our study is to analyze the dif-
ferences in EGFR expression in OLD subtypes such as 
OLP and OLL when diagnostic  histological criteria are 
employed; and also to correlate EGFR expression with 
the main clinical and histological features.
Material and Methods
We have studied 44 biopsies obtained from patients 
clinically and histopathologically diagnosed with OLD 
in the Oral Medicine and Oral and Maxillofacial Pa-
thology Unit (Dental Clinic Service of the University 
of Basque Country/EHU), during the period of January 
2006 to June 2008. Out of 44 patients, 30 (68.2%) were 
females and 14 (31.8%) males, with a mean age of 56.4 
years (range 31-82 years). 
Clinical and histopathological data were collected using 
a protocol based on previous studies (2,3,12). Briefly, 
the clinical data like sex, age, type and site of the le-
sions were collected. Regarding histopathological fea-
tures, presence or absence of the main epithelial and 
inflammatory infiltrate characteristics were recorded 
and graded in mild, moderate or severe in each case. 
Cases were clinically classified in: Group C1 with 26 
(59.1%) cases with only papular reticular lesions, and 
Group C2 with 18 (40.9%) cases with papular reticular 
and other lesions such as atrophic, erosive, and ulcera-
tive and/or plaque lesions. As inclusion criterion, none 
of the patients should have been receiving treatment for 
OLD at the time of the study or previous to diagnosis. 
The mean follow up time was 43.5 months (range 20-78 
months), period in which no malignant transformation 
was observed in any of the cases.
- Histology and Immunohistochemistry 
The cases were classified histopathologically following 
the diagnostic criteria proposed by van der Meij and 
van der Waal (2) in an “histologically typical of OLP” 
(Group HT) with 23 (52.3%) cases, and “histological-
ly compatible with OLP” (Group HC) with 21 (47.7%) 
cases. Briefly, HT cases had to show: (1) well-defined 
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superficial “band like” predominantly lymphocytic 
chronic inflammatory infiltrate, (2) epithelial basal cell 
degeneration, and (3) absence of dysplasia; and HC cas-
es did not show either one or none of the characteristics 
described for HT cases. Cases with epithelial dysplasia 
were excluded from the study. Samples of oral mucosa 
without epithelial and/or inflammatory alterations and 
OSCC were employed as controls. All cases and con-
trols underwent an hematoxylin and eosin standard his-
tological procedure as well as conventional immunohis-
tochemical analysis.
For immunohistochemical analysis, 4ųm paraffin 
sections were treated with a citrate buffer solution at 
100°C for 2 minutes as antigen retrieval and incubat-
ed using the Novolink Polymer Detection Kit (Novo-
castra®, New Castle Upon Tyne, UK) following the 
manufacturer s´ instructions. All cases were incubated 
with the primary prediluted monoclonal antibody anti-
EGFR protein (clon 31G7, Zymed Labs®, Camarillo 
CA, USA.) for 1 hour at room temperature. The anti-
body employed has been tested previously in other 
studies (18,22). For visualization, sections were colored 
with the substrate/chromogen 3,3= -diaminobenzidine 
(DAB) using the Polymer Detection Kit (Novocastra®, 
New Castle Upon Tyne, UK) showing a visible brown 
precipitate at the antigen site. Based on previous studies 
(23), and considering the EGFR expression in controls, 
a semiquantitative analysis of the expression percent-
age and the expression pattern of epithelial cells was 
performed, using the Soft Image System Cell A soft-
ware (Olympus®, Munster, Germany). Immunohisto-
chemical analysis was performed randomly in 5 fields 
by 3 observers (DC, JCC and JMA), independently and 
without knowledge of clinical data, using a light optic 
microscope Olympus® BX41 20x objective and 10x ocu-
lar. A consensus agreement was reached for any given 
sample when discrepancies existed among observers for 
any given sample. The epithelial EGFR cell expression 
was assessed as follows: mild expression when <20% of 
epithelial cells were positive, moderate expression when 
≥20% but <40% of epithelial cell were positive and se-
vere expression when ≥40% of cells were positive. For 
statistical analysis, the variables were dichotomized in 
“low EGFR expression” when the expression was mild 
or moderate, and “overexpression of EGFR” when it 
was severe. The expression pattern was assessed in: 
membrane pattern (Mm), cytoplasmatic pattern (Ct) 
and mixed membrane-cytoplasmatic pattern (Mm-Ct), 
and the expression intensity in mild, moderate and se-
vere. For statistical analysis the cellular expression was 
dichotomized in mild and moderate-severe intensity.
The study was approved by the Ethics, Investigation and 
Teaching Committee (CEISH) of the University of the 
Basque Country/EHU. The data underwent a descrip-
tive and comparative statistical analysis with X2 Pear-
son method and Fisher exact test, using the statistical 
software SPSS (Version 15.0, SPSS Inc., Chicago, IL).
Results
As expected, given the location of proliferating cells, 
the epithelial expression of EGFR in controls of non-
affected oral mucosa was confined to basal and para-
basal cell layers with an Mm expression and scarce Ct 
expression pattern. In contrast, OSCC controls showed 
an intense EGFR expression in the periphery and the 
center of neoplastic nests, with a mixed Mm-Ct severe 
expression pattern (Fig. 1). 
All cases showed EGFR expression in basal and para-
basal epithelial cells. Thirty-nine cases (88.6%) showed 
EGFR expression in the spinous layer and only in 5 
(11.4%) cases reached the superficial layers. EGFR over-
expression was recognized in 35 (79.5%) cases and low 
expression in 9 (20.5%) (Fig. 1). We think that chronic 
inflammation mediators might be the main reason of 
this high number of cases with EGFR overexpression, 
rather than a higher malignant risk. All cases showed 
an Mm expression pattern, but in 31 (70.5%), we also 
observed a Ct pattern, which was mild and moderate-
severe in 13 (41.9%) and 18 (58.1%) cases respectively. 
This was an interesting finding because main EGFR ex-
pression pattern in non-affected oral mucosa controls 
was Mm rather than Ct, which in turn was intense in 
OSCC controls.
We did not find significant differences in EGFR ex-
pression between the clinical and histological groups 
(p>0.05) (Table 1), suggesting that the expression of 
EGFR in OLD subtypes does not seem to be completely 
related with the severity of the clinical lesions, in other 
words, epithelial integrity (ulcers and/or erosions) did not 
affect significantly EGFR expression. Out of the cases 
with EGFR overexpression, 17 (38.6%) cases showed a 
moderate-severe Ct expression pattern (Fig. 1), 6 (40%) 
and 11 (84.6%) cases from HT and HC groups respec-
tively showing a significant difference (p=0.016) (Table 
1). This finding suggests, that when specific histological 
diagnostic criteria (2) are applied there are differences 
in the cellular localization of EGFR in OLD subtypes, 
regardless of other histological features like inflamma-
tory infiltrate intensity and/or epithelial thickness or 
integrity.
When we analyzed the histopathological features of 
cases with EGFR overexpression, we only observed 
significant differences regarding the keratinization 
type, since 19 (54.3%) of these cases showed parakera-
tosis compared with only 1 (11.1%) case without EGFR 
overexpression (p=0.027) (Table 2). To this respect, 
we thought that is difficult to consider this associa-
tion, since parakeratosis is frequently observed in OLP 
and OLL samples. However, it might be reasonable to 
observe modifications in the epithelial lining features 
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Fig. 1. EGFR expression of not altered oral mucosa (a) (20x) and OSCC (b) (40x) controls. 
Mild EGFR cytoplasmatic expression pattern in HT case (c) (40x) and moderate-severe in HC 














Group C2 15 (83,3 %) 6 (54,5) 
Group HT 18 (78,9 %) 6 (40) 
0,016 
Group HC 17 (81,0 %) 11 (84,6) 
Table 1. Clinical and histological cases of OLD with EGFR overexpression and cytoplasmatic 
expression pattern.
* Moderate/Severe.
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such as keratosis, hyperkeratosis, atrophy or basal cell 
degeneration; or from the inflammatory infiltrate such 
as the intensity, cellular types and pattern with different 
EGFR expression intensity. This suggests that EGFR 
expression intensity not always has a histological vis-
ible effect in OLD subtypes.
Discussion
OLD includes different chronic inflammatory proc-
esses like OLP and OLL, characterized clinically by 
the presence of white lineal papular lesions in the oral 
mucosa (1). The malignant potential of these processes 
is controversial and sometimes difficult to analyze due 
to the lack of defined and uniform diagnostic criteria 
employed in each study (7-10). Several years ago, van 
der Meij and van der Waal (2) proposed a clinical and 
histological diagnostic criteria to differentiate typical 
cases of OLP from those that were only compatible 
called OLL. These authors (2) demonstrated that when 
these criteria were applied, only cases diagnosed as 
OLL showed an evident risk for malignant transforma-
tion (7,8). Although a clear clinical and histopathologi-
cal differentiation of OLP and OLL is critical, an im-
munohistochemical analysis of these processes would 
give valuable information about their molecular profiles 
and their possible malignant risk.
The EGFR protein is a biomarker of early carcinogen-
esis (24,25), overexpressed in several oral premalignant 
diseases (13,14,16). Moreover, EGFR has an synergic 
participation with other carcinogenesis biomarkers like 
cyclooxygenase-2 (COX-2), inducible nitric oxide syn-
thase (iNOS) (26-28). iNOS is associated with EGFR 
through the stimulation of STAT-3 (Signal Transducer 
and Activator of Transcription-3) and with COX-2 
through the synthesis of prostaglandin (PGE2) (16). The 
upregulation of STAT-3 and COX-2 expression maintain 
directly and/or indirectly the EGFR intracellular path-
ways, due to activation of other proteins involved in this 
process, enhancing oral carcinogenesis in OPML such 
as OLP and OLL (16,24). To this respect, previously 
we have demonstrated the overexpression of COX-2 in 
these same samples (27). These results may support the 
synergy between EGFR and COX-2 and highlights the 
possible prognostic implications of this molecular inter-
action in OLP and OLL.
Our study has demonstrated that EGFR is overexpressed 
in a great percentage of OLD cases, showing no dif-
ferences between the clinical and histological groups. 
These findings may suggest that the clinical type of 
lesions does not always reflect the molecular features 
of OLD processes, in other words, the presence of an 
erosive or ulcerative lesion “clinically more aggressive 
and striking”, not necessarily implies an overexpression 
of EGFR, and in the same way, the presence of reticu-
lar white lesion “clinically less aggressive or striking“, 




NO (%) YES (%) p 
Parakeratosis* 1 (11,1) 19 (54,3) 
0,027 
Orthokeratosis* 8 (88,9) 16 (45,7) 
Hyperkeratosis* 5 (55,6) 12 (34,3) 
>0,05 
Atrophy* 2 (22,2) 9 (25,7) 
Lengthen epithelial crest  1 (11,1) 11 (31,4) 
Dyskeratosis (Civatte bodies) † 6 (66,7) 21 (60) 
Basal degeneration* 9 (100) 32 (91,4) 
Inflammatory infiltrate* 2 (22,2) 15 (42,9) 
Lymphocytes* 8 (88,9) 24 (68,6) 
Plasmocytes* 1 (11,1) 10 (28,6) 
Band like inflammatory infiltrate † 6 (66,7) 28 (80) 
Perivascular inflammatory infiltrate † 1 (11,1) 5 (14,3) 
Superficial inflammatory infiltrate † 5 (55,6) 17 (48,6) 
Deep inflammatory infiltrate † 4 (44,4) 18 (51,4) 
Table 2. EGFR overexpression according to the main histopathological features observed.
*Moderate-Severe, † Presence of characteristic.
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is worth mentioning that these findings were also ob-
served in a previous study (27) when we analyze the 
COX-2 expression in these same cases. The histological 
HT and HC groups showed no significant differences in 
the EGFR overexpression, suggesting that the presence 
or absence of a particular histological feature like an in-
tense inflammatory infiltrate and/or extensive epithelial 
basal cell degeneration or thickness it is not related with 
EGFR expression in OLP and OLL. These data indicate 
the existence of other molecular mechanisms implicated 
in EGFR expression in OLD subtypes. 
Due to the lack of clinical and histological separation in 
similar studies (20,21), the comparison of our results is 
difficult. However, our results contrast with those ob-
tained by Ebrahimi et al. (20) where, although they do 
not mention the type of clinical lesion of their cases, 
they observed a low EGFR expression in OLP samples 
compared with controls. These authors (20) suggest 
that high p53 expression in OLP or the presence of mu-
tated EGFR protein (EGFR vIII) may explain the low 
EGFR expression in OLP. p53 protein is one of several 
control mechanisms of EGFR expression (24,25), thus 
its overexpression may explain EGFR low expression. 
However, several studies (13,17,29) have pointed out 
that EGFR mutations in OLP and other OPML is an 
uncommon event. Moreover, several studies (16,25,29) 
have demonstrated that the expression of EGFR vIII is 
mainly observed in late oral carcinogenesis stages and 
always accompanied with the expression of the wild 
type EGFR protein. In this sense, the antibody used in 
this study recognizes both wild and mutated EGFR pro-
tein, which makes it difficult to ensure the main type of 
EFGR protein detected in our study. However, based on 
previous studies (13,17,29) and considering the low per-
centage of cases with expression of EGFR vIII in OLD 
and other OPML, we assume that the main protein de-
tected in our study is the wild type EGFR protein. Simi-
lar to our results, Kumagai et al. (21) observed EGFR 
overexpression in all OLP samples, and additionally 
they observed overexpression of EGFR ligands (am-
phireguline, epireguline y HB-EGF [Heparin-binding-
EGF like growth factor]) and decreased expression of 
the ligands EGF and TGF-alpha. Supported by their re-
sults, these authors (21) suggest that EGFR overexpres-
sion in OLP may contribute to the carcinogenesis of this 
disorder. These authors (21) have only included reticular 
lesions, therefore the comparison with our results is not 
totally valid in this sense. However, we did not observe 
significant differences in EGFR expression among the 
Group C1 (papular-reticular) cases. 
Most of our samples showed a mixed Mm-Ct EGFR 
expression pattern which is in concordance with other 
studies (13,21). However, we observed significant differ-
ences between the histological groups, since high per-
centage of HC cases showed a Ct moderate-severe ex-
pression pattern compared with HT cases. Other studies 
(20,21) that analyze the EGFR expression in OLP make 
no reference to this finding. It is worth to note  that this 
Ct expression pattern was not present in controls of non-
affected oral mucosa but was intense in OSCC controls. 
To this respect, Muller et al. (18) have linked previously 
the Ct EGFR expression pattern with malignant poten-
tial in patients with HNC. These authors (18) observed 
that Ct EGFR expression pattern in HNC cell lines was 
associated with nodal metastasis and increased resist-
ance to tyrosine-kinase inhibitors. Other studies (13), 
have demonstrated in samples of normal oral mucosa 
adjacent to HNC, that the localization of Ct EGFR ex-
pression and the ligand TGF-alpha was the same, and 
furthermore, the intensity and extension of this expres-
sion increased proportionally to the severity of the le-
sion. Similarly, Srinivasan et al. (17) have observed that 
Ct EGFR expression in OPML proportionally increased 
with the severity of the epithelial dysplasia. These au-
thors suggest (17) that the Ct EGFR expression could 
be due to the internalization of the receptor once it has 
been activated by extracellular ligands, or alternatively, 
due to it being transport to its final location after being 
synthesized. If the presence of an increased Ct EGFR 
expression in HT or OLL cases is associated or may 
contribute to a greater malignant potential as was dem-
onstrated previously by van der Meij et al. (7,8) is dif-
ficult to ascertain with these results, but may be worth 
considering. 
We have demonstrated that EGFR overexpression was 
not associated with any particular clinical or histological 
feature, suggesting that different and/or more complex 
molecular mechanisms are involved in this process. The 
main cause of EFGR overexpression in OLD samples re-
mains unknown. However, some authors (22) have found 
that EGFR overexpression in other OPML with malig-
nant transformation was associated with an increased 
EGFR gen copy number, which can also be a possibility 
that need to be investigated in OLD subtypes.
Considering the low rate of malignant transformation 
of OLP (<1%) (9,11), it is obvious that the high percent-
age of cases with EGFR overexpression herein observed 
will not suffer a malignant transformation, since seve-
ral genetic alterations would be necessary to make that 
possible. Nevertheless, the EGFR and COX-2 overex-
pression previously demonstrated (27) in these samples, 
may enhance the carcinogenic process in those geneti-
cally susceptible cases. Therefore, these molecular al-
terations can give us valuable information about intrac-
ellular pathways altered in OLD subtypes like OLP and 
OLL. So, with all the previous background, we can pro-
pose two possible scenarios: the first that HC subtypes 
lesions with EGFR overexpression and increased Ct 
expression pattern may have a different biological be-
havior from those HT subtypes lesions, which might be 
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possibly associated with a higher malignant potential; 
the second scenario, may be that these differences in 
the EGFR expression pattern, could be the result of dif-
ferent molecular profiles involved directly or indirectly 
in EGFR immunoexpression in OLP and OLL, which 
is probably determined by etiological factors of each 
process and may not be related with malignant poten-
tial. However, regardless the prognostic implication of 
these immunohistochemical differences, we have dem-
onstrated that although the clinical and histopathologi-
cal features are very similar in all OLD processes, there 
are molecular differences in each OLD subtype.
We did not observe significant association between 
EGFR expression and any particular histological fea-
ture, except for keratinization type, since more than 
50% of the cases with EGFR overexpression showed 
parakeratosis. This finding has not been reported previ-
ously by other authors (20,21). We do not know exactly 
the meaning of this finding, or even if it has clinical 
relevance. However, considering that parakeratosis is a 
common finding in OLD samples it is very difficult to 
evaluate this association. Nevertheless, what we do con-
sider relevant is the lack of association of EGFR overex-
pression with the presence and/or intensity of some par-
ticular features from the epithelial lining and inflam-
matory infiltrate. Inflammatory intensity and epithelial 
thickness are some of the features classically associated 
with the activity of OLD lesions. We believe that these 
findings may have relevance in those cases with mild 
histological activity at diagnosis and then develop ma-
lignant transformation in a short period of time.
We can conclude that there is a high EGFR overexpres-
sion in OLD subtypes, which increase their susceptibil-
ity to the EGFR stimulation effects like cell prolifera-
tion, differentiation, apoptosis inhibition, angiogenesis, 
migration and cellular invasion. Neither the clinical 
type nor particular histological features were associated 
with EGFR overexpression. Cases considered as “his-
tologically compatible” (HC) or OLL show a greater 
cytoplasmic EGFR expression, suggesting biological 
differences with HT cases. The long term follow up of 
these OLD patients will give us more consistent infor-
mation about the significance of EGFR expression and 
malignant potential in these processes. However, fur-
ther studies are needed to ascertain the exact prognostic 
value of EGFR expression in different types of OPML 
like OLP and OLL.
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